All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
"We're enjoying the one-two punch," Mark Goldsmith, president and CEO of Revolution Medicines Inc., told BioWorld after the Redwood City, Calif.-based firm inked an oncology partnership with Sanofi SA covering its SHP2 program. In return for an exclusive license for global commercialization of any approved products targeting SHP2, the Paris-based pharma agreed to provide Revolution with $50 million up front and up to $500 million in development and regulatory milestone payments and to fund R&D for the joint SHP2 program, which remains, for now, under Revolution's direction.